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Clade C is one of the most prevalent genetic subtypes of human immunodeficiency virus type 1 (HIV-1) in
the world today and one of the least studied with respect to neutralizing antibodies. Most information on HIV-1
serology as it relates to neutralization is derived from clade B. Clade C primary isolates of HIV-1 from South
Africa and Malawi were shown here to resemble clade B isolates in their resistance to inhibition by soluble CD4
and their sensitivity to neutralization by human monoclonal antibody immunoglobulin G1b12 and, to a lesser
extent, 2F5. Unlike clade B isolates, however, all 16 clade C isolates examined resisted neutralization by 2G12.
Infection with clade C HIV-1 in a cohort of female sex workers in South Africa generated antibodies that
neutralized the autologous clade C isolate and T-cell-line-adapted (TCLA) strains of clade B. Neutralization
of clade B TCLA strains was much more sensitive to the presence of autologous gp120 V3 loop peptides
compared to the neutralization of clade C isolates in most cases. Thus, the native structure of gp120 on primary
isolates of clade C will likely pose a challenge for neutralizing antibody induction by candidate HIV-1 vaccines
much the same as it has for clade B. The autologous neutralizing antibody response following primary infection
with clade C HIV-1 in South Africa matured slowly, requiring at least 4 to 5 months to become detectable. Once
detectable, extensive cross-neutralization of heterologous clade C isolates from South Africa was observed,
suggesting an unusual degree of shared neutralization determinants at a regional level. This high frequency of
cross-neutralization differed significantly from the ability of South African clade C serum samples to neutralize
clade B isolates but did not differ significantly from results of other combinations of clade B and C reagents
tested in checkerboard assays. Notably, two clade C serum samples obtained after less than 2 years of infection
neutralized a broad spectrum of clade B and C isolates. Other individual serum samples showed a significant
clade preference in their neutralizing activity. Our results suggest that clades B and C are each comprised of
multiple neutralization serotypes, some of which are more clade specific than others. The clustering of shared
neutralization determinants on clade C primary HIV-1 isolates from South Africa suggests that neutralizing
antibodies induced by vaccines will have less epitope diversity to overcome at a regional level.
An important goal in the development of an effective human
immunodeficiency virus type 1 (HIV-1) vaccine is to overcome
the extensive genetic heterogeneity of the virus. Nucleotide
sequence comparisons have been used to define three groups
of the virus known as group M (main), group O (outlier), and
group N (non-M, non-O) (50, 69). Group M is further divided
into 10 phylogenically related genetic subtypes (clades A, B, C,
D, F1, F2, G, H, J, and K) that, together with a growing
number of circulating intersubtype recombinant forms, com-
prise the majority of HIV-1 variants in the world today. Clade
C is emerging as most prevalent, being common in India (15,
16, 31, 41) and the southern African countries of Botswana,
Zimbabwe, Malawi, Mozambique, and South Africa (7, 8, 25,
26, 60, 64, 79, 81). Clade B is dominant in North America and
Western Europe and has been a major focus for vaccine de-
velopment (27). It is uncertain whether vaccines that are ulti-
mately effective against clade B will be capable of targeting
other genetic subtypes of the virus.
The uncertain relevance of genetic subtype to HIV-1 vac-
cines is owed in part to a poor understanding of the immuno-
type diversity of the virus as it relates both to cellular and
humoral immunity. The fact that genetic subtypes tend to clus-
ter geographically raises the possibility that distinct immuno-
types of the virus have evolved along similar lines and, al-
though a growing body of evidence suggests that this may not
be true in a strict sense (4, 12, 29, 38, 56, 61, 82), additional
studies seem warranted. For example, with respect to humoral
immunity, the sporadic neutralizing activity of sera from HIV-
1-infected individuals appears to be independent of genetic
subtype (38, 56, 61, 82). That observation has led to a general
notion that genetic subtype does not predict the neutralization
serotype of the virus. An exception has been noted for clades
B and E (E is now known as recombinant subtype A/E [32]),
which appear to consist of different neutralization serotypes
relative to each other. That conclusion was based on results of
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checkerboard assessments made with four serum samples and
virus isolates from each clade (47) and when serum pools from
both clades, selected for high neutralizing antibody titers, were
tested with a larger panel of clade B and E isolates (45).
The concept of HIV-1 immunotypes may be particularly
relevant to neutralizing antibodies. Neutralizing antibodies tar-
get the surface gp120 and transmembrane gp41 envelope gly-
coproteins of the virus (62, 65) and could be a valuable anti-
viral immune response to generate with vaccines (44, 49, 52).
These glycoproteins exist as a trimolecular complex of gp120-
gp41 heterodimers (17, 24, 43, 83) and are essential for virus
entry. Antibody-mediated neutralization of HIV-1 may take
place either by blocking gp120 from binding its cellular recep-
tor (CD4) or coreceptor (CCR5 and CXCR4) or by preventing
gp41 from mediating fusion with the target cell membrane (2,
18, 21, 22, 28, 30, 39, 40, 74, 84). Both glycoproteins display an
unusual degree of sequence variation that gives rise to complex
epitopes. One manifestation of this variation during infection
is the evolution of neutralization escape variants. For example,
serum from individuals infected with clade B HIV-1 often fails
to neutralize contemporaneous and later virus isolates but
neutralizes earlier isolates from the respective individuals quite
potently (1, 3, 6). Epitopes responsible for primary isolate
neutralization by serum samples from HIV-1-infected individ-
uals remain largely unknown.
Genetic variation also affects the higher-order structure of
the native envelope glycoprotein complex, having a profound
effect on antigenicity. For example, certain N-glycans and ter-
tiary folds in the gp120 core can render primary HIV-1 isolates
resistant to neutralization by soluble CD4 (sCD4) and many
antibody specificities compared to T-cell-line-adapted (TCLA)
strains of the virus (20, 68, 72, 85). This is very common for
epitopes in the third variable cysteine-cysteine loop (V3 loop)
of gp120 (5, 73, 77). Antibodies in sera from infected individ-
uals and vaccinated volunteers may have potent neutralizing ac-
tivity against the matched (autologous) HIV-1 variant but
those antibodies have limited neutralizing activity against het-
erologous variants (14, 34, 55, 58, 63). This is especially true in
the case of vaccine-elicited antibodies (9, 48). Some excep-
tions include a small number of human monoclonal antibodies
(e.g., 2G12, immunoglobulin G1b12 [IgG1b12], and 2F5) and
sera from a subset of HIV-1-infected long-term nonprogres-
sors, in which cases a broad spectrum of HIV-1 isolates are
neutralized (10).
Immunotype diversity could adversely impact the ability to
develop a single HIV-1 vaccine that is broadly effective on a
global scale. Alternatively, it may be possible to tailor vaccines
to match the virus variant(s) circulating in specific regions
targeted for vaccination. In either case, the ability to identify
and predict the relevant immunotypes of the virus would has-
ten vaccine efforts. With respect to neutralizing antibodies,
very few virus isolates and serum samples belonging to clade C
have been characterized, and in fact, very little is known about
the neutralization properties of clade C isolates and serum
samples from South Africa. The present studies were con-
ducted to define the neutralization properties of these virologic
and serologic reagents in preparation for future vaccine clinical
trials in South Africa and other areas where clade C is com-
mon. Our results identify important similarities and differences
between clades B and C of HIV-1. Moreover, we provide
evidence that neutralization serotypes of HIV-1 may cluster
geographically within a clade. The implications of these find-
ings for vaccine development are discussed.
MATERIALS AND METHODS
Viruses, cells, and serum samples. Eight clade B and 17 clade C primary
HIV-1 isolates were used in these studies. All clade B isolates possessed an R5
phenotype and were obtained during early seroconversion from subjects in the
United States, Trinidad, and Italy (9). Nine clade C isolates (which begin with the
prefix Du) were isolated in 1998 from female sex workers recruited from four
truck stops along the major trucking route between Durban and Johannesburg,
South Africa. These women were participating in a multicenter clinical trial of a
potential vaginal microbicide (78). Details of the recruitment procedures are
documented elsewhere (67). The women were screened monthly for sexually
transmitted infections including HIV. HIV-1 seroconversion was assessed by
enzyme-linked immunosorbent assay (ELISA) (Abbott, Chicago, Ill.) and con-
firmed by using the Vironostika HIV Uniform II micro-ELISA 4 system (Om-
nimed, Madison, Wis.). All HIV-1-positive tests were further confirmed by the
Institute of Tropical Medicine, Antwerp, Belgium–-the central laboratory for the
multicenter trial. At each visit, women were given pre- and posttest HIV-1
counseling and were provided with intensive condom counseling. Sexually trans-
mitted diseases were treated according to the South African syndromic manage-
ment guidelines. Virus was isolated within 4 months of initial seroconversion
from five of these sex workers (Du123, 3 months; Du151, 1.5 months; Du156, 1
month; Du172, 1 month; Du422, 4 months) and at later time points from four
additional sex workers (Du174, 19.5 months; Du179, 21 months; Du204, 12
months; Du368, 7.5 months). Sequence analysis of gag, pol, and env confirmed
that all South African isolates were clade C and lacked intersubtype recombina-
tion (Williamson et al., submitted for publication).
Eight additional clade C isolates (which begin with the prefix S) were obtained
from individuals attending the sexually transmitted disease clinic of the Lilongwe
Central Hospital in Malawi (64). These isolates were shown to be clade C by
serologic and sequence analysis of the V3 loop of gp120 (64). All clade C isolates
from Africa had an R5 phenotype except for Du179, which was R5X4 and
induced syncytium formation in MT-2 cells. Coreceptor usage of clade C isolates
from South Africa was assessed in U87.CD4 cells transfected to express either
CCR5 or CXCR4 as described (57). The coreceptor usage of the remaining
isolates was reported previously (9, 64).
Viruses were isolated by peripheral blood mononuclear cell (PBMC) coculture
as described (53, 57). All primary isolates were of a low passage number (three
passages or fewer) in PBMC exclusively. Stocks of the TCLA strains, HIV-1IIIB,
HIV-1MN, and HIV-1SF-2, were generated in H9 cells (54). All virus stocks were
made cell free by filtration (filter pore size, 0.45-m) and stored in aliquots at
80°C until use. Two additional cell lines used in neutralization assays, MT-2
and CEMx174, have been described previously (35, 70). PBMC were maintained
in RPMI 1640 containing 20% heat-inactivated fetal bovine serum and supple-
mented with gentamicin (50 g/ml) and human interleukin-2 (4%). Growth
medium for the H9, MT-2, and CEMx174 cells consisted of RPMI 1640 con-
taining 12% heat-inactivated fetal bovine serum supplemented with gentamicin
(50 g/ml).
Serum samples presumed to be clade B were obtained from HIV-1-infected
individuals attending the Duke University Medical Center Infectious Diseases
Clinic in Durham, N.C. The individuals had been infected with HIV-1 for 2
years and donated serum between 1998 and 2000. A previous study assessed
these serum samples for neutralizing activity against the eight clade B primary
isolates used here (9). Additional serum samples were collected at multiple time
points from each of the nine sex workers in South Africa. Due to personal
preference, participation in a structured treatment-interruption protocol, or non-
availability, no subjects were on antiretroviral therapy at the time of serum
collection; this was done to avoid possible in vitro antiviral activity of the drugs
that might be misinterpreted as neutralizing antibody activity at low serum
dilutions. All sera were heat inactivated at 56°C for 45 min.
Monoclonal antibodies and sCD4. IgG1b12, 2G12, and 2F5 are human mono-
clonal antibodies that bind conserved epitopes and cross-neutralize a variety of
TCLA strains and primary isolates (11, 23, 36, 66, 75, 76). The epitope for
IgG1b12 is located in the CD4-binding domain of gp120 and is sensitive to
mutations in V2 and C3 (51). 2G12 recognizes an epitope in the C2-V4 region of
gp120 that involves sites of N glycosylation (76). 2F5 recognizes a linear epitope
in the ectodomain of gp41 having the amino acid sequence ELDKWA (59).
sCD4 comprising the full-length extracellular domain of human CD4 and pro-
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duced in Chinese hamster ovary cells was obtained from Progenics Pharmaceu-
ticals, Inc. (Tarrytown, N.Y.).
DNA sequencing. The DNA sequence of the V3 loop of gp120 was determined
by direct sequencing of amplified products generated by RT-PCR. PCR primers,
with the reverse outer primer used as the reverse transcriptase primer in the
cDNA synthesis step, were o-env, 6201 to 6227 and 9067 to 9095; i-env, 6815 to
6838 and 7322 to 7349 (numbered using the HIV-1 HXBr sequence, Los Alamos
HIV sequence database). Amplified DNA fragments were purified using the
QIAQUICK PCR Purification Kit (Qiagen, Valencia, Calif.). Sequencing was
done using the Sanger dideoxyterminator strategy with fluorescence dyes at-
tached to the dideoxynucleotides, and the sequence determination was made by
electrophoresis using an ABI 377 sequencer. A portion of the gag (939 bases), pol
(834 bases), and gp120-gp41 junction (340 bases) was also sequenced and shown
to be clade C with no evidence of recombination (Williamson et al., submitted).
gp120-V3 peptides. Peptides corresponding to amino acid sequences in the V3
loop of clade C isolates were synthesized, purified, and analyzed by SynPep
Corporation (Dublin, Calif.). The HIV-1IIIB V3 peptide was purchased from
Sigma (Saint Louis, Mo.), whereas the HIV-1MN V3 peptide was purchased from
American BioTechnologies, Inc. (Cambridge, Mass.). All peptides were 90%
pure as judged by high-pressure liquid chromatography and mass spectrometry.
Neutralizing antibody assays. Neutralization of primary isolates was measured
in PBMC by using a reduction in p24 Gag antigen synthesis as described previ-
ously (9). Briefly, 500 50% tissue culture infective doses of virus were incubated
with various dilutions of test samples (serum, monoclonal antibodies, and sCD4)
in triplicate for 1 h at 37°C in 96-well U-bottom culture plates. PHA-PBMC were
added and incubated for one day. The cells were then washed three times with
growth medium and resuspended in 200 l of fresh growth medium. Culture
supernatants (25 l) were collected twice daily thereafter and mixed with 225 l
of 0.5% Triton X-100. The 25 l of culture fluid removed each day was replaced
with an equal volume of fresh growth medium. Concentrations of p24 Gag
antigen in Triton X-100 lysates were measured in an antigen capture ELISA as
described by the supplier (DuPont/NEN Life Sciences, Boston, Mass.). Concen-
trations of p24 in virus control wells (virus plus cells but no test serum) were
determined for each harvest day. Concentrations in all remaining wells were
determined for a harvest day that corresponded to a time when p24 production
in virus control wells was in an early linear phase of increase that exceeded 3
ng/ml, which is when optimum sensitivity is achieved in this assay (87). The limit
of detection in the p24 ELISA was 0.1 ng of p24/ml. Neutralization titers are
given as the reciprocal of the minimum serum dilution (calculated prior to the
addition of cells) that reduced p24 synthesis by 80% relative to a negative control
serum sample from a healthy, HIV-1-negative individual.
Neutralization assay for TCLA strains were performed in either MT-2 cells
(HIV-1IIIB and HIV-1MN) or CEMx174 cells (HIV-1SF2) by using neutral red to
quantify the percentage of cells that survived virus-induced killing (54). Briefly,
500 50% tissue culture infective doses of virus were incubated with multiple
dilutions of serum samples in triplicate for 1 h at 37°C in 96-well flat-bottom
culture plates. Cells were added and the incubation continued until most but not
all of the cells in virus control wells (cells plus virus but no serum sample) were
involved in syncytium formation (usually 4 to 6 days). Cell viability was quantified
by neutral red uptake as described (54). Neutralization titers are defined as the
reciprocal serum dilution (before the addition of cells) at which 50% of cells
were protected from virus-induced killing. A 50% reduction in cell killing cor-
responds to an approximate 90% reduction in p24 Gag antigen synthesis in this
assay (9). Each set of assays included a positive control serum that had been
assayed multiple times and had a known average titer.
V3-specific neutralizing antibodies were assessed by incubating diluted serum
samples (diluted with an equal volume of phosphate-buffered saline, pH 7.4) for
1 h at 37°C in the presence and absence of V3 peptide (50 g/ml). Titers of
neutralizing antibodies were then determined in either the PBMC assay (in the
case of primary isolates) or the MT-2 cell assay (in the case of HIV-1IIIB and
HIV-1MN) as described above.
ELISA. V3 peptide-specific binding antibodies were assessed by ELISA in
Nunc (Roskilde, Denmark) Immuno plates (MaxiSorb F96) using alkaline phos-
phatase-conjugated, goat anti-monkey IgG as described (19). Plasma samples
were assayed in duplicate at a 1:50 dilution, and values are given as the average
absorbance at a wavelength of 405 nm.
Statistical analyses. Differences in positive response rates (i.e., positive neu-
tralization at any serum dilution) between genetic subtypes of the virus for a
given serum sample were tested for statistical significance by using the two-sided
Fisher’s exact test. Differences in mean log neutralizing antibody titers between
genetic subtypes of the virus for a given serum sample were tested by using the
two-sided Wilcoxon rank sum test. For overall differences in either the positive
response rates or mean log neutralizing antibody titers between genetic subtypes
of the virus, pairwise results were pooled as a sample and tested for significance
by using the nonparametric Wilcoxon sign rank test. All differences were con-
sidered significant if P was 0.05. Analyses of overall differences included only
heterologous virus-serum pairs. This was done to eliminate bias, since only the
Du samples contained autologous pairs.
RESULTS
Neutralization of clade C primary HIV-1 isolates with sCD4
and monoclonal antibodies. Primary isolates from eight sub-
jects in South Africa and eight subjects in Malawi were char-
acterized in neutralization assays with sCD4 and three broadly
neutralizing human monoclonal antibodies. These clade C iso-
lates all exhibited a high level of resistance to inhibition by
sCD4 (Table 1). Of the three monoclonal antibodies tested,
IgG1b12 was most effective, neutralizing five of eight isolates
from South Africa and four of eight isolates from Malawi at
doses in the range of 1.8 to 50 g/ml. Monoclonal antibody
2F5 neutralized two isolates from Malawi but none from South
Africa. A third monoclonal antibody, 2G12, failed to neutralize
all 16 clade C isolates tested. The broad resistance of clade C
primary isolates to neutralization by 2G12 was in striking con-
trast to the ability of this same preparation of 2G12 to neu-
tralize six of eight clade B isolates tested previously (9). Con-
trol assays performed with TCLA strains and primary isolates
belonging to clade B confirmed no loss of activity of the sCD4
and monoclonal antibodies used in these experiments (data
not shown).
Neutralizing antibody response following infection with
clade C HIV-1. Serum samples collected at multiple time
points from nine South African sex workers were assayed for
neutralizing activity against the autologous virus isolate and
three TCLA strains of clade B HIV-1. All subjects developed
a neutralizing antibody response against their own virus (Fig.
TABLE 1. Neutralization sensitivity of HIV-1 clade C isolates as measured with sCD4 and human monoclonal antibodies
Reagent
ID80 (g/ml) for isolatea
South African Malawian
Du123 Du151 Du156 Du172 Du174 Du179 Du368 Du422 S080 S021 S009 S018 S007 S180 S017 S103
rsCD4 50 50 50 50 50 41 50 50 50 50 50 50 50 50 50 50
2G12 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50
IgG1b12 16 50 50 29 50 50 30 23 33 50 50 2 50 50 50 <2
2F5 50 50 50 50 50 50 50 50 50 49 50 50 50 50 50 7
a Values below each virus strain are the minimum concentration of sCD4 and monoclonal antibodies 2G12, IgG1b12, and 2F5 required to achieve an 80% reduction
in p24 synthesis in PBMC (ID80). Positive neutralization is shown in boldface type.
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1). The magnitude of this response varied between individuals
and was relatively potent in most cases (titers of 100 in seven
of nine cases). Although the timing of serum collection did not
permit a refined assessment of the temporal response, it is
accurate to say that autologous neutralizing antibodies were
undetectable for at least the first 4 to 5 months of infection in
three subjects (Du123, Du151, and Du422). Despite this delay,
all three subjects eventually mounted a potent autologous neu-
tralizing antibody response. Autologous neutralizing antibod-
ies were low or undetectable at early time points and later rose
in magnitude for subjects Du123, Du151, Du156, Du172, and
Du422 as evidence that these five study subjects were in an
early stage of seroconversion at the time of their enrollment.
Autologous neutralizing antibodies in these five subjects were
assessed with virus that was obtained shortly after infection.
Autologous neutralizing antibodies in the remaining cases
were measured with virus that was obtained either before
(Du368) or after (Du174, Du179, and Du204) the time of first
serum collection (an estimated 6 to 15 months from initial
ELISA positivity). Of these latter cases, virus from subject
Du368 was neutralized potently by all serum samples collected
5.5 months later and thereafter. Virus isolated at month 21
from subject Du179 was neutralized weakly by serum samples
obtained at month 15 and was neutralized potently by serum
samples obtained at month 25 and thereafter. Virus from sub-
ject Du174, isolated at month 19.5, was neutralized weakly or
not at all by serum collected at months 13, 18, 30, and 34. A
second study subject, Du204, had a similar weak autologous
neutralizing antibody response.
TCLA strains belonging to clade B HIV-1 were highly sen-
sitive to neutralization by the clade C serum samples. Overall
neutralization-sensitivity with clade C serum samples was HIV-
1MN  HIV-1SF2  HIV-1IIIB (Fig. 1). Neutralizing antibodies
were sometimes detected with clade B TCLA strains before
being detected with the autologous clade C isolate. Moreover,
the potency of neutralization detected with TCLA strains usu-
ally exceeded the potency detected with the autologous isolate.
Two additional observations are worth noting. First, as men-
FIG. 1. Neutralizing antibody response over time in infected individuals in South Africa. Neutralizing antibodies were measured in PBMC with
the early autologous isolate and in either MT-2 or CEMx174 cells with the clade B TCLA strains IIIB (MT-2), MN (MT-2), and SF2 (CEMx174).
Results that were negative (neutralization titers of 4 for autologous isolates and 20 for IIIB, MN, and SF2) were assigned a value of 1 for
representation.
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tioned above, sera from 5 subjects were capable of neutralizing
the autologous isolate obtained prior to serum collection
(Du123, 10.5 months; Du151, 8 months; Du156, 3 months;
Du172, 8 months; Du422, 9 months). Autologous isolates in
these cases were obtained 1 to 3 months after initial serocon-
version and, as such, could closely resemble the transmitted
variant that drove the initial antibody response, leading to
antibodies that neutralized the early variant. Two subjects en-
rolled later in infection (Du179 and Du368) had detectable
autologous neutralizing antibodies that increased in magnitude
over the observation period. Autologous isolates in these two
cases were obtained 21 and 7.5 months after infection and
therefore could be variants that escaped an earlier neutralizing
antibody response. In this event, the neutralizing antibodies we
detected might have arisen as a de novo antibody response to
escape epitopes. Although earlier isolates were not available to
test this possibility, a later isolate from subject Du179 (36.5
months) was sensitive to neutralization (titer 108) by serum
samples collected at months 25, 30, and 32.5, suggesting that
the neutralization determinants were not evolving at a fast
pace.
Antibody response to the V3 loop of gp120. V3-specific an-
tibodies were assessed by ELISA and in competitive neutral-
ization assays with peptides from five different clade C isolates
from South Africa (Du123, Du151, Du172, Du179, and
Du422), the clade C consensus sequence (37), and the clade B
TCLA strains HIV-1MN and HIV-1IIIB. The amino acid se-
quence of each V3 peptide is shown in Table 2. Sera from
South African subjects reacted strongly with the autologous
peptide and exhibited broad cross-reactivity with heterologous
clade C peptides (Fig. 2). Reactivity was somewhat diminished
in the case of the consensus clade C peptide and more so in the
case of the IIIB peptide. Reactivity to the HIV-1MN peptide
was variable, being relatively strong for subjects Du151 and
Du179 and low to moderate for subjects Du123 and Du422.
To determine whether these V3-specific antibodies had neu-
tralizing activity, serum samples were preincubated with V3
peptides and then assayed for neutralizing activity against the
autologous virus and two TCLA strains (Fig. 3). A major frac-
tion of autologous neutralizing activity in serum Du179 was
blocked by the matched Du179 V3 peptide, suggesting the
presence of neutralizing antibodies directed against the V3
loop of this virus. As a control, the HIV-1MN peptide had no
effect on the autologous neutralizing activity of this serum
sample. Matched V3 peptides and the HIV-1MN V3 peptide
had no effect on the autologous neutralizing activity of four
other clade C serum samples. By comparison, the HIV-1MN-
specific neutralizing activity of all five serum samples was dra-
FIG. 2. ELISA reactivity to V3 peptides. Serum samples (1:50 dilution) were evaluated by ELISA for the presence of antibodies that could bind
individual peptides derived from the V3 loop of the indicated virus strains. The amino acid sequence of each peptide is shown in Table 2. The
dotted line represents the cutoff value for positive reactivity (twice the optical density [OD] of a control serum sample from a healthy,
HIV-1-negative individual). The following serum samples were obtained after the estimated number of months of infection: Du123 (13.5 months),
Du151 (11.3 months), Du172 (8 months), Du179 (25 months), Du422 (17 months). CC, clade C consensus sequence.
TABLE 2. Amino acid sequences of V3 peptides
HIV-1 isolate Amino acid sequencea
CC..................................................................................T R P N N N T R K S I R I - - G P G Q T F Y A T G D I I G D I R Q
Du123 ............................................................................I R P N N N T R K S I R I - - G P G Q T F Y A T N D I I G D I R Q
Du151 ............................................................................T R P N N N T R K S I R I - - G P G Q T F Y A T D A I I G N I R E
Du172 ............................................................................T R P S N N T R K S V R I - - G P G Q T F F A T G D I I G D I R Q
Du179 ............................................................................T R P G N N T R K S I R I - - G P G Q A F Y - T N H I I G D I R Q
Du422 ............................................................................T R P N N N T R K S V R I - - G P G Q T F Y A T G A I I G D I R E
MN................................................................................. N K R K R I H I - - G P G R A F Y T T K N I I G T I
IIIB ................................................................................ N N N T R K S I R I Q R G P G R A F V T I G K – I G
a Amino acids that differ from the consensus clade C sequence (CC) are shown in boldface type
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matically reduced in the presence of matched V3 peptides and
the HIV-1MN V3 peptide but not the HIV-1IIIB V3 peptide. In
addition, the HIV-1IIIB-specific neutralizing activity was re-
duced in the presence of matching V3 peptide and the HIV-
1IIIB V3 peptide but not the HIV-1MN V3 peptide. We note
that the reduction in HIV-1IIIB-specific neutralization was mi-
nor in one of three cases examined (Du123). Due to sample
availability and low neutralization titers against HIV-1IIIB, the
remaining two samples could not be tested in these competi-
tion assays with HIV-1IIIB.
Analysis of intra- and interclade neutralization. A checker-
board analysis was performed with clade B and C virus isolates
and serum samples. Clade C serum samples were selected from
the South African sex workers at a time when neutralizing
activity was detected with the autologous virus and TCLA
strains. Clade B serum samples were obtained from individuals
in North Carolina who had documented HIV-1 infection for
2 years. These same clade B serum samples were assayed
recently against the clade B viruses in our panel (9), and there-
fore, those results were used in our comparative analyses. We
FIG. 3. Ability of V3 peptides to out-compete the neutralizing activity of clade C serum samples from South Africa. Serum samples shown in
Fig. 1 were evaluated for neutralizing activity in the presence and absence of gp120 V3 peptides (50 g/ml) as described in Materials and Methods.
Autologous (Autol.) V3 peptide refers to a peptide bearing the amino acid sequence of the virus from the subject who was the source of serum
listed on the x axis. The top panel shows autologous virus-serum combinations, the middle panel shows clade C serum samples assayed with the
HIV-1MN virus, and the bottom panel shows clade C serum samples assayed with the HIV-1IIIB virus. ID80, 80% inhibitory dose.
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caution that a potential source of error in our checkerboard
assaysisthelackofsequenceinformationtoconfirmthegeneticsub-
type of virus from our presumed clade B serum donors from
North Carolina. These subjects were presumed to be infected
with clade B based on the high incidence of clade B in North
America. We also note that our partial genetic and sero-
logic characterization of the clade C isolates from Malawi does
not entirely eliminate the possibility that these are recombi-
nant viruses.
Cross-neutralization within and between genetic subtypes
was readily apparent (Table 3). The clade C isolates appeared
to be more sensitive to neutralization overall compared to
clade B isolates. Specifically, the Du isolates were neutralized
70% of the time (excluding autologous virus-serum combina-
tions) by Du serum samples, and 54% of the time by clade B
serum samples. Moreover, the Malawi isolates were neutral-
ized 48% of the time by Du serum samples. By comparison,
clade B isolates were neutralized 25% of the time by Du serum
samples (Table 3) and 27% of the time by clade B serum sam-
ples (9). Overall trends were analyzed statistically based on pos-
itive neutralization frequencies and mean neutralization titers.
Only the positive response rates between Du and clade B iso-
lates tested with Du serum samples were found to be statisti-
cally significant (Table 4). We note that no significant differ-
ences were identified based on mean neutralization titers
(Table 4).
A number of clade-specific reactivities were observed within
the overall analysis: (i) isolate Du174 was neutralized prefer-
entially by clade C sera (P  0.01 based on response rate), (ii)
serum Du151 exhibited a preferential neutralization of clade C
isolates from South Africa (P  0.01 based on response rate;
P  0.02 based on mean neutralization titer), (iii) serum NLS-
02 exhibited a preferential neutralization of clade C isolates
from South Africa (P  0.01 by both criteria), and (iv) serum
Du204 exhibited a preferential neutralization of clade C iso-
lated from South Africa (P  0.05 based on mean neutraliza-
tion titer). Notably, one serum sample from the Du cohort
(Du179) neutralized 16 of 16 clade C isolates and six of eight
clade B isolates (Table 3).
A broader assessment of cross-neutralizing activity with 50
heterologous primary HIV-1 isolates was performed on a small
subset of serum samples for which an adequate supply of
serum was available. These particular serum samples had po-
tent neutralizing activity against the early autologous clade C
isolate (titer  100) and were able to neutralize TCLA strains
belonging to clade B. They were assayed at a 1:20 dilution with
the 50 primary isolates to be selective for relatively potent
heterologous neutralization specificities. The heterologous
primary isolates consisted of the 8 clade B and 16 clade C
isolates listed in Table 3 plus an additional 26 clade B isolates.
The results are summarized in Table 5 and do not include
autologous virus-serum combinations. Serum Du151 neutral-
ized 40% of the isolates as evidence that this serum sample
contains broadly cross-reactive neutralizing antibodies. Serum
samples Du156 and Du368 were much less cross-reactive but
nonetheless neutralized 7 to 17% of isolates. No clade-specific
preferences were observed with these two serum samples (P 
1.00).
DISCUSSION
The neutralization properties of primary isolates and serum
samples from clade C HIV-1-infected individuals were charac-
terized and compared to clade B. Our goal was to develop
standard virologic reagents and to acquire information that
would benefit vaccine design. A major focus was placed on
South Africa because of the high rates of HIV-1 transmission
and the lack of information on neutralizing antibodies in that
country. A particular emphasis was placed on a group of fe-
male sex workers located at multiple stops along a major truck-
ing route between Durban and Johannesburg. These women
were participating in HIV-1 prevention programs as part of a
microbicide trial and were screened monthly for HIV-1 sero-
conversion. Virus isolates and serum samples were available in
some cases very soon after infection, which made it possible to
examine the autologous and heterologous neutralizing activity
of the earliest antibodies generated.
All but one clade C isolate possessed the R5 biologic phe-
notype that is typical of transmitted variants. These isolates
(eight from South Africa and eight from Malawi) resembled
R5 clade B isolates in their sensitivity to neutralization by some
but not all serologic reagents. Shared properties included a
high level of resistance to inhibition by sCD4 and the frequent
neutralization by monoclonal antibody IgG1b12. Resistance to
sCD4 is a general property that distinguishes primary isolates
from TCLA strains (20) and is thought to reflect the exposure
of critical epitopes in and around the CD4 binding site of
gp120 as affected by N-linked glycans and tertiary folds in the
native gp120 molecule (85). It may be presumed that we pre-
served the sCD4-resistant phenotype of these clade C isolates
by passing them a minimum number of times in PBMC exclu-
sively (71). Many sCD4-resistant variants of HIV-1 are difficult
to neutralize with monoclonal antibodies and sera from in-
fected individuals. The IgG1b12 epitope, which overlaps the
CD4 binding domain of gp120 (51), is an exception in that
neutralization by this monoclonal antibody is not predicted by
sCD4 sensitivity. For example, the 89.6 and 89.6P variants of
simian-human immunodeficiency virus are both moderately
sensitive to inhibition by sCD4 yet exhibit a striking dichotomy
in their sensitivity to neutralization by IgG1b12 (19). The abil-
ity of IgG1b12 to neutralize many sCD4-resistant variants of
clade C HIV-1 is additional evidence that this antibody spec-
ificity would be highly beneficial for broadly effective vaccina-
tion.
Another monoclonal antibody, 2F5, that is known to be
effective against primary isolates was only able to neutralize 2
of 16 clade C isolates here. Since this low frequency was no
different statistically from the three of eight clade B isolates
neutralized by this same batch of 2F5 (9), the neutralizing
activity of 2F5, like that of IgG1b12, does not appear to dis-
tinguish clade B from clade C. A much different outcome
occurred with the 2G12 monoclonal antibody in that it failed to
neutralize all 16 clade C isolates from South Africa and Malawi
up to the highest dose tested (50 g/ml). 2G12 has been shown
to neutralize primary HIV-1 isolates from multiple clades (9,
23, 46, 75, 76), but very high doses were needed to neutralize
the small number of clade C isolates tested in those studies (75,
86). We conclude that 2G12 has very poor neutralizing activity
against clade C isolates relative to other clades. It seems unlike-
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ly that the neutralizing specificity of 2G12 will have an impact
in regions where clade C is prevalent, except in cases where it
is synergistic with other neutralizing antibody specificities (86).
Our analysis of sequential serum samples from a group of
South African sex workers infected with clade C HIV-1 showed
a delay in autologous neutralizing antibody production follow-
ing primary infection of at least 4 to 5 months. That delay was
similar to clade B infection (55, 63) and could be due to either
early immunologic dysfunction, the poor immunogenicity of
the envelope glycoproteins, or a combination of these factors.
Following the delay, a potent autologous neutralizing antibody
response was detected in most cases (titers  100) as evidence
that the B-cell response to critical epitopes eventually matured.
Despite potent neutralizing antibodies, one individual (Du151)
never gained control of her viremia and progressed to AIDS
rapidly. We do not know the status of this person’s HIV-1-
specific cellular immune response, nor were we able to deter-
mine whether a neutralization escape variant arose that might
explain the rapid progression.
In addition to neutralizing the autologous isolate, clade C
serum samples from South Africa neutralized TCLA strains of
clade B HIV-1 with a level of potency similar to clade B serum
samples. This is evidence that the antibody specificities for
TCLA HIV-1 neutralization are conserved between clades B
and C. In support of this notion, antibodies in clade C serum
samples bound peptides corresponding to the V3 loop of clade
B and C gp120, which is a major target for the neutralization of
clade B TCLA strains (5, 73, 77). Although the amino acid
sequence of the V3 loop of clades B and C can be quite
different (37, 64), they appear to share antigenic features rec-
ognized by monoclonal antibodies (33). This may explain why
the neutralizing activity of clade C serum samples against clade
B TCLA strains was sensitive to the presence of V3 loop
peptides. The inability of V3 loop peptides to block autologous
neutralization of clade C primary isolates in four of five cases
examined, this despite the presence of antibodies to the autol-
ogous V3 peptide, suggests that certain epitopes in the V3 loop
of clade C primary isolates are poorly antigenic relative to
TCLA strains. A similar phenomenon has been described for
clade B (5, 73, 77). This dichotomy in antigenicity is an indi-
cation that epitope exposure on the native envelope glycopro-
tein complex of clade C primary isolates will pose a challenge
for neutralizing antibody induction by candidate HIV-1 vac-
cines much the same as it has for clade B (52, 85).
Primary isolates of clade B and C HIV-1 were further com-
pared in checkerboard neutralization assays that differed from
those in previous reports in several ways: (i) a large number of
clade C isolates and serum samples were included, (ii) virus
isolates were obtained early in infection, and (iii) the clade C
serum samples corresponded to an early stage of neutralizing
antibody production. In general, the earliest neutralizing anti-
bodies to be detected in an HIV-1-infected individual have a
limited range of specificity (14, 55). It was therefore unexpect-
ed to find 70% of heterologous clade C virus-serum combina-
tions testing positive from South Africa. This high frequency is
unusual and, with the exception of sera from some long-term
nonprogressors (13, 63), has not be documented previously.
The extensive cross-neutralization within the South African
serum samples and virus isolates may be an indication of
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ing for vaccine efforts, as it suggests that neutralizing antibod-
ies will have less epitope diversity to overcome at a regional
level. The broad implications of this concept depend in part on
the geographic range of the shared determinant that defines
the corresponding neutralization serotypes. Less epitope diver-
sity would be expected if multiple subjects in our cohort were
infected by the same individual. Shared determinants might
also arise as a consequence of serial transmission of selected
isolates in these sex workers. Early evidence in South Africa
suggested multiple introductions of the virus into the country,
with the diversity observed being greater than one would ex-
pect from founder-type effects such as seen in Thailand (8, 79).
Similarly, within this sex worker cohort, the analysis of the
relationships between gag, pol, and env sequences showed rel-
atively high diversity, and little phylogenetic clustering of se-
quences was detected (Williamson et al., submitted). Single-
donor and serial transmission of selected isolates are therefore
not obvious explanations for our results. However, full-length
sequencing does show reliable clustering of two of the isolates
(Du151 and Du422), suggesting that at least for these two
isolates there was a common source in the not-too-distant past
(80). Moreover, we cannot be certain that these female sex
workers were not infected multiple times to give rise to a cross-
reactive polyvalent neutralizing antibody response. Along this
same line, it has been reported that initial virus populations are
more heterogeneous in women than in men immediately fol-
lowing transmission (42). Additional studies will be needed to
clarify the events that gave rise to the cross-neutralizing anti-
body responses in the South African subjects and how those
events might impact vaccine development.
The 70% positive neutralization rate within the set of South
African clade C viruses and serum samples differed signifi-
cantly only from the overall ability of these same serum sam-
ples to neutralize clade B isolates. This case of clade-specific
neutralization did not extend to other combinations in our
checkerboard assays with clade B and C reagents, suggesting
that clades B and C are comprised in part of overlapping
neutralization serotypes. Evidence that the overlap was only
partial comes from a number of individual cases of clade-
specific neutralization. One example is a clade C isolate
(Du174) that was neutralized preferentially by clade C serum
samples. In addition, two South African clade C serum samples
neutralized South African clade C isolates in a specific manner.
Taken together with the selective neutralizing activity of 2G12,
these examples reflect subtle associations between genetic sub-
type and neutralization serotype that have gone unnoticed in
previous studies, owing in part to the complexity of the neu-
tralization determinants on the virus and the limited number of
clade C reagents used in the past. One unexpected finding was
the preferential neutralization of clade C isolates by a pre-
sumed clade B serum sample. Unfortunately, a lack of se-
quence information on the virus from this individual makes it
possible that infection was with a non-clade B virus. Nonethe-
less, this is an additional case of a serum that recognized a
neutralization serotype found in clade C that was rarely de-
tected in clade B. Our combined results are an indication that
within each genetic subtype are multiple neutralization sero-
types, some of which are more clade-specific than others.
During the course of our studies we discovered two individ-
uals in South Africa (Du151 and Du179) whose serum after
less than 2 years of infection neutralized a large number of
clade B and C primary isolates. This cross-neutralizing activity
was not unlike that of sera from some HIV-1-infected long-
term nonprogressors (13, 63) and appears to be relatively
unique for recent seroconverters. The cross-reactive neutraliz-
ing activity could be due to host factors, viral factors, or a
combination of the two. It also serves to confirm that clades B
and C consist in part of overlapping neutralization serotypes.
The viral envelope glycoproteins from these two individuals
are interesting candidates for vaccine development.
It seems possible that some neutralization serotypes track
more with geography than with genetic subtype, as was sug-
gested by our observations in a cohort of sex workers in South
Africa infected with clade C HIV-1. If generally true, targeted
immunogens might prove beneficial for vaccines in this and
other parts of the world. The selection of immunogens for such
tailored vaccines will require extensive surveys of virus isolates
and serum samples. Alternatively, new approaches for cross-
reactive neutralizing antibody induction are under investiga-
tion that may make tailoring efforts unnecessary (52). With few
exceptions (e.g., 2G12 epitope), an immunogen that generates
antibodies capable of neutralizing many clade B isolates may
be expected to neutralize many clade C isolates and vice versa.
Until such immunogens become available, efforts to induce
neutralizing antibodies with candidate HIV-1 vaccines might
benefit the most by including envelope glycoproteins from one
or more strains of the virus that predominate in the specific







Du Du vs B 0.03 0.31
B Du vs B 0.13 0.13
Du Mw vs B 0.19 0.50
Du Du vs Mw 0.25 0.13
a Du, clade C from South Africa; B, clade B; Mw, clade C from Malawi.
b Overall differences in either the positive neutralization response rate or
mean log neutralizing antibody (NAb) titers between genetic subtypes of the
virus were tested for significance by using the nonparametric Wilcoxon sign rank
test. Differences were considered significant if P was 0.05. To eliminate bias,
results of autologous serum-virus pairs in the Du samples were excluded from
analysis, since this was the only group where autologous pairs were present.
TABLE 5. Cross-neutralizing activity of serum samples from three
subjects infected with clade C HIV-1
Subject








Du151 12 (34) 8 (53) 20 (40)
Du156 6 (17) 2 (13) 8 (16)
Du368 3 (9) 1 (7) 4 (8)
a Serum samples from subjects Du151 (17.3 months), Du156 (17 months), and
Du368 (27 months) were assayed at a 1:20 dilution with 35 clade B and 15
heterologous clade C primary HIV-1 isolates. Neutralization was considered
positive if p24 synthesis was reduced 80% relative to a negative control (serum
from a healthy, HIV-1-negative individual). Values do not include autologous
virus-serum combinations.
b This is the fraction and percent of isolates neutralized for the 50 isolates
total.
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regions targeted for vaccination. We add as a cautionary note
that it is not clear at this time what level of neutralizing anti-
body induction and clinical benefit will be achieved with those
envelope glycoproteins.
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